rifaximin hepatic encephalopathy
Selected indexed studies
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. (Cochrane Database Syst Rev, 2023) [PMID:37467180]
- Rifaximin treatment in hepatic encephalopathy. (N Engl J Med, 2010) [PMID:20335583]
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (PLoS One, 2022) [PMID:35471992]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Rifaximin treatment in hepatic encephalopathy. (2010) pubmed
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (2022) pubmed
- The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial. (2021) pubmed
- Hepatic encephalopathy - recent advances in treatment and diagnosis. (2023) pubmed
- Hepatic Encephalopathy in Children. (2024) pubmed
- Hepatic encephalopathy in dogs and cats. (2016) pubmed
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. (2023) pubmed
- Hepatic encephalopathy. (2022) pubmed
- Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial. (2024) pubmed
- Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management. (2025) pubmed